These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2327 related items for PubMed ID: 7184382

  • 1. [Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy].
    Jimbow K, Takahashi H, Ishihara K, Hayasaka K, Kukita A, Seki Y, Ikeda S, Terakado T.
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1942-9. PubMed ID: 7184382
    [Abstract] [Full Text] [Related]

  • 2. [Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy (part II)].
    Ishihara K, Hayasaka K, Ikeda S, Terakado T, Kukita A, Seki Y, Jimbow K, Suzuki M.
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):467-73. PubMed ID: 6703721
    [Abstract] [Full Text] [Related]

  • 3. [Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin].
    Maeda K, Miura S, Kawamura M, Jimbow K.
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2434-7. PubMed ID: 6497401
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    Umeda T, Aoki K, Yokoyama A, Ohara H, Hayashi O, Tanaka K, Nishioka K.
    J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Adjuvant chemotherapy of malignant melanoma of the female genital organs].
    Inoue S, Shibata S, Tohya T, Munemura M, Fujisaki S, Maeyama M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jan; 38(1):135-8. PubMed ID: 3456398
    [No Abstract] [Full Text] [Related]

  • 13. [A case report of anorectal malignant melanoma showing a complete response after DTIC/ACNU/VCR therapy].
    Sasaki S, Kojima T, Hidemura A, Hatanaka K, Uekusa T, Ishimaru M.
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1999-2002. PubMed ID: 20948273
    [Abstract] [Full Text] [Related]

  • 14. [Chemotherapy of malignant melanoma].
    Ishihara K.
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):23-7. PubMed ID: 7529980
    [Abstract] [Full Text] [Related]

  • 15. Complete remission of metastatic clear cell sarcoma with DAV chemotherapy.
    Fujimoto M, Hiraga M, Kiyosawa T, Murakami T, Murata S, Ohtsuki M, Nakagawa H.
    Clin Exp Dermatol; 2003 Jan; 28(1):22-4. PubMed ID: 12558622
    [Abstract] [Full Text] [Related]

  • 16. [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
    Inoi T, Mojamdar M, Ichihashi M, Mishima Y.
    Nihon Hifuka Gakkai Zasshi; 1984 Jan; 94(1):39-43. PubMed ID: 6433083
    [No Abstract] [Full Text] [Related]

  • 17. Chemoimmunotherapy for melanoma with DTIC, ACNU, VCR and OK432: evaluation of new combinations for survival rates, side effects and cellular immunity.
    Jimbow K, Yanbe H, Nishio C.
    J Dermatol; 1981 Aug; 8(4):259-66. PubMed ID: 7028826
    [No Abstract] [Full Text] [Related]

  • 18. [A combination chemotherapy of ACNU and DTIC for advanced malignant melanoma].
    Domyo M, Ogawa M, Inagaki J, Horikoshi N, Ezaki K, Inoue K, Aiba K, Nagata T, Miyamoto H.
    Gan To Kagaku Ryoho; 1982 May; 9(5):874-9. PubMed ID: 6964041
    [Abstract] [Full Text] [Related]

  • 19. [An autopsy case of neurocutaneous melanosis associated with intracerebral malignant melanoma].
    Sawamura Y, Abe H, Murai H, Tashiro K, Doi S.
    No To Shinkei; 1987 Aug; 39(8):789-95. PubMed ID: 3322333
    [Abstract] [Full Text] [Related]

  • 20. Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly.
    Matsumoto T, Yokota K, Sawada M, Sakakibara A, Shibata S, Yasue S, Tomita Y, Yatsuya H, Akiyama M.
    J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1514-20. PubMed ID: 23198869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 117.